In July 2021, we entered into an agreement whereby we obtained an 80.2% interest in DomaniRx, LLC (“DomaniRx”), a variable interest entity under GAAP. We have the power to direct the majority of the activities of DomaniRx that most significantly impact its economic performance, the obligation to absorb losses and the right to receive benefits from DomaniRx. Accordingly, we determined that we are the primary beneficiary of DomaniRx and consolidate its results.

During the three months ended June 30, 2026, the Board of DomaniRx authorized a mandatory additional capital contribution in accordance with each member’s ownership interest in DomaniRx in the amount of $75.0 million. We received cash capital contributions from our joint venture partners totaling $14.9 million during the three months ended June 30, 2026. Our cash capital contribution was paid in July 2026.

The carrying value of the assets and liabilities associated with DomaniRx included in our unaudited condensed consolidated balance sheet at June 30, 2026 and December 31, 2025, which are limited for use in its operations and do not have recourse against our general credit or our senior secured credit facilities, are as follows:


	June 30,		December 31,
	2026		2025
Assets:
Cash and cash equivalents	$	31.9	$	28.4
Prepaid expenses and other current assets		0.1		0.5
Intangible assets		241.7		232.7
Other assets		18.2		12.0
Liabilities:
Other liabilities		1.1		1.1